Physician profile
Owen E Mccormack
NPI 1689607681
$6,346.65
in general payments reported to CMS, 2019-2025
35 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $553 · 2021: $529 · 2022: $313 · 2023: $1,298 · 2024: $858 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,851.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,802.88 | 2019-2025 | Biktarvy, Yeztugo |
| Novo Nordisk INC | $889.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Viiv Healthcare Company | $556.57 | 2019-2025 | Cabenuva, Rukobia, Apretude |
| Merck Sharp & Dohme LLC | $519.24 | 2019-2025 | Delstrigo, Pifeltro, Gardasil 9 |
| Lilly USA, LLC | $459.71 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $297.15 | 2019-2024 | Airsupra, Farxiga |
| Pfizer INC. | $238.84 | 2021-2025 | |
| Exact Sciences Corporation | $199.75 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.78 | 2020-2025 | Jardiance |
| Abbvie INC. | $166.80 | 2021-2025 | |
| Glaxosmithkline, LLC. | $134.92 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $133.21 | 2019-2022 | |
| Inspire Medical Systems, INC. | $84.23 | 2023-2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.05 | 2020-2025 | Xifaxan, Trulance |
| Emd Serono, INC. | $57.33 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $50.66 | 2019-2020 | |
| Noven Therapeutics, LLC | $48.90 | 2024 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $46.20 | 2023 | Rexulti |
| Abbott Laboratories | $46.14 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $44.28 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.85 | 2022 | |
| Amarin Pharma, INC. | $37.02 | 2020 | |
| Dexcom, INC. | $22.23 | 2025 | Dexcom G6 Transmitter |
| Napo Pharmaceuticals INC | $21.72 | 2025 | Mytesi |
| Radius Health, INC. | $21.67 | 2024 | Tymlos |
| Hikma Pharmaceuticals USA | $21.37 | 2020 | |
| Ibsa Pharma INC. | $18.92 | 2025 | Tirosint, Flector, Licart |
| Azurity Pharmaceuticals, INC. | $17.70 | 2025 | Alvesco |
| Supernus Pharmaceuticals, INC. | $17.40 | 2023 | Qelbree |
| Sumitomo Pharma America, INC. | $17.21 | 2025 | Gemtesa |
| Eisai INC. | $17.12 | 2021 | |
| Genentech USA, INC. | $15.80 | 2019 | |
| Hologic Sales and Service, LLC | $14.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.88 | 2020 | |
| Shire North American Group INC | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Owen Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.